UB Paderborn / Katalog / Suche / in CDI

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

Annals of oncology, 2022-10, Vol.33 (10), p.1052-1060

2022

Volltextzugriff (PDF)

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

ESMO open, 2021-10, Vol.6 (5), p.100273, Article 100273

2021

Volltextzugriff (PDF)

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis

Annals of oncology, 2023-02, Vol.34 (2), p.173-185

2023

Volltextzugriff (PDF)

Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’: [ESMO Open Volume 6, Issue 5, October 2021, 100273]

ESMO open, 2021-12, Vol.6 (6), p.100345-100345, Article 100345

2021

Volltextzugriff (PDF)

P376 Efficacy of ozanimod in vedolizumab-exposed patients with ulcerative colitis: a phase 3 True North post hoc analysis

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i507-i508

2023

Volltextzugriff (PDF)

DOP43 Rapidity of ozanimod-induced symptomatic response and remission in patients with moderately to severely active Ulcerative Colitis: Results from the induction period of True North

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i092-i093

2022

Volltextzugriff (PDF)

SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

Annals of oncology, 2021-07, Vol.32, p.S213-S214

2021

Volltextzugriff (PDF)

P585 Duration of response to ozanimod after treatment withdrawal: results from the phase 3 True North study

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i713-i714

2023

Volltextzugriff (PDF)

P752 Predictors of time to relapse upon ozanimod withdrawal in patients with moderately to severely active ulcerative colitis

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i882-i884

2023

Volltextzugriff (PDF)

Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles d’un doublet de chimiothérapie à base de sels de platine (CT) vs 4 cycles de chimiothérapie en 1ère ligne (1L) de traitement du cancer bronchique non à petites cellules (CBNPC) au stade avancé : données du suivi à 2 ans de l’étude CheckMate 9LA (CM 9LA)

Revue des maladies respiratoires actualités, 2022-01, Vol.14 (1), p.198-198

2022

Volltextzugriff (PDF)

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Journal of thoracic oncology, 2022-02, Vol.17 (2), p.289-308

2022

Volltextzugriff (PDF)

Non-alcoholic fatty liver disease in type 1 diabetes: Prevalence and pathophysiology

Frontiers in endocrinology (Lausanne), 2022-12, Vol.13, p.1031633-1031633

2022

Volltextzugriff (PDF)

S15 Efficacy of Ozanimod in Patients With Ulcerative Colitis Who Were Previously Exposed to Vedolizumab: True North Post Hoc Analysis

The American journal of gastroenterology, 2022-12, Vol.117 (12S), p.S4-S4

2022

Volltextzugriff (PDF)

Role of Oxidative Stress and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 in Nonalcoholic Fatty Liver Disease

International journal of molecular sciences, 2023-07, Vol.24 (14), p.11271

2023

Volltextzugriff (PDF)

The Life Insurance Market in Albania and the Factors that Affect its Development

International Journal of Innovation and Economic Development, 2022, Vol.8 (3), p.39-45

2022

Volltextzugriff (PDF)

S98 Ozanimod Efficacy and Safety in Older Patients With Ulcerative Colitis: A Post Hoc Analysis From True North

The American journal of gastroenterology, 2022-12, Vol.117 (12S), p.S25-S25

2022

Volltextzugriff (PDF)

S14 Duration of Response After Ozanimod Withdrawal: Phase 3 True North Study Results

The American journal of gastroenterology, 2022-12, Vol.117 (12S), p.S4-S4

2022

Volltextzugriff (PDF)

S731 Ozanimod Is an Effective Oral Treatment for Patients With Ulcerative Colitis Regardless of Baseline Endoscopic Disease Distribution: A Post Hoc Analysis of the Phase 3 True North Study

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e513-e514

2022

Volltextzugriff (PDF)

S825 Efficacy of Ozanimod in Vedolizumab-Exposed Patients With Ulcerative Colitis: A Phase 3 True North Post Hoc Analysis

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e593-e594

2022

Volltextzugriff (PDF)

S811 Evaluation of Ozanimod Efficacy and Safety in Older Patients With Ulcerative Colitis: Post Hoc Analysis From the Phase 3 True North Study

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e580-e581

2022

Volltextzugriff (PDF)

Porter Framework vs A More Extended Framework

International Journal of Religion, 2024-05, Vol.5 (9), p.115-124

2024

Volltextzugriff (PDF)

S76 An Interim Analysis of 2 Years of Continuous Ozanimod Treatment From the True North Open-Label Extension Study

The American journal of gastroenterology, 2022-12, Vol.117 (12S), p.S20-S20

2022

Volltextzugriff (PDF)

Recycling Behavior Case of Shkodra, Albania

RGSA : Revista de Gestão Social e Ambiental, 2024, Vol.18 (1), p.e04949-15

2024

Volltextzugriff (PDF)

S723 Duration of Response to Ozanimod After Treatment Withdrawal: Results From the Phase 3 True North Study

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e506-e507

2022

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis

Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’: [ESMO Open Volume 6, Issue 5, October 2021, 100273]

P376 Efficacy of ozanimod in vedolizumab-exposed patients with ulcerative colitis: a phase 3 True North post hoc analysis

DOP43 Rapidity of ozanimod-induced symptomatic response and remission in patients with moderately to severely active Ulcerative Colitis: Results from the induction period of True North

SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

P585 Duration of response to ozanimod after treatment withdrawal: results from the phase 3 True North study

P752 Predictors of time to relapse upon ozanimod withdrawal in patients with moderately to severely active ulcerative colitis

Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’: ESMO Open Volume 6, Issue 5, October 2021, 100273

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Non-alcoholic fatty liver disease in type 1 diabetes: Prevalence and pathophysiology

S15 Efficacy of Ozanimod in Patients With Ulcerative Colitis Who Were Previously Exposed to Vedolizumab: True North Post Hoc Analysis

Role of Oxidative Stress and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 in Nonalcoholic Fatty Liver Disease

The Life Insurance Market in Albania and the Factors that Affect its Development

S98 Ozanimod Efficacy and Safety in Older Patients With Ulcerative Colitis: A Post Hoc Analysis From True North

S14 Duration of Response After Ozanimod Withdrawal: Phase 3 True North Study Results

S731 Ozanimod Is an Effective Oral Treatment for Patients With Ulcerative Colitis Regardless of Baseline Endoscopic Disease Distribution: A Post Hoc Analysis of the Phase 3 True North Study

S825 Efficacy of Ozanimod in Vedolizumab-Exposed Patients With Ulcerative Colitis: A Phase 3 True North Post Hoc Analysis

S811 Evaluation of Ozanimod Efficacy and Safety in Older Patients With Ulcerative Colitis: Post Hoc Analysis From the Phase 3 True North Study

Porter Framework vs A More Extended Framework

S76 An Interim Analysis of 2 Years of Continuous Ozanimod Treatment From the True North Open-Label Extension Study

Recycling Behavior Case of Shkodra, Albania

S723 Duration of Response to Ozanimod After Treatment Withdrawal: Results From the Phase 3 True North Study

Suchergebnisse filtern